Adding Darzalex (daratumumab) to a treatment combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone increased the proportion of newly diagnosed patients with multiple myeloma showing…
Sleep apnea can drive the development of aggressive multiple myeloma in mice resistant to the cancer, a study found, suggesting that the sleep disorder is…
In a continuing effort to support and advance early-phase multiple myeloma studies in the United Kingdom, Myeloma UK is launching a patient-focused research…
Janssen has asked the U.S. Food and Drug Administration (FDA) to approve a new subcutaneous (under-the-skin) formulation of Darzalex (daratumumab) as a…
A genomic rearrangement involving the immunoglobulin lambda (IgL) gene is predictive of resistance to immunomodulatory agents and poor outcomes among multiple myeloma patients, a new…
The U.S. Food and Drug Admnistration (FDA) has agreed to review Sanofi’s biologics license application (BLA) for its investigational antibody, isatuximab, as a potential…
The U.S. Food and Drug Administration (FDA) has lifted its hold on the CANOVA Phase 3 clinical trial, which is evaluating the experimental therapeutic…
The U.S. Food and Drug Administration (FDA) has approved — with conditions — Xpovio (selinexor) tablets, in combination with the corticosteroid…
Scientists discovered a set of genes that work as an “on/off switch” for malignant multiple myeloma cancer cells, which may shed light into new…
The U.S. Food and Drug Administration (FDA) has approved Janssen‘s Darzalex (daratumumab), used in combination with Revlimid…
